Ecnoglutide Phase 2 trial (NCT05111912)
A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 206
- actual
- Start
- 30 Nov 2021 (actual)
- Primary completion
- 16 Nov 2022 (actual)
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Cohort A | Experimental | Drug: XW003 | Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily. |
| Cohort B | Experimental | Drug: XW003 | Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily. |
| Cohort C | Experimental | Drug: XW003 | Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily. |
| Cohort D | Active comparator | Drug: Saxenda | Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage change in participants body weight (%) from the Baseline | Week 26 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportions of participants with body weight loss ≥5%, ≥10% and ≥15% of the Baseline | Week 26 |
| Absolute change in body weight (kg) of participants | Week 26 |
| Changes in waist circumference and hip circumference (cm) in participants | Week 26 |
| Change in BMI in participants | Week 26 |
| Change in fasting plasma glucose (FPG) | Week 26 |
| Change in fasting serum insulin | Week 26 |
| Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Week 26 |
| Changes in fasting lipids (triglyceride, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) | Week 26 |
| Number and severity of treatment-emergent adverse events (TEAEs) | Week 26 |
| Number and severity of new and ongoing gastrointestinal (GI) disorder (nausea, vomiting, diarrhea, and constipation) events by week | Week 26 |
| Vital signs - participants' blood pressure change | Week 26 |
| Vital signs - participants' pulse rate change | Week 26 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.